{"protocolSection":{"identificationModule":{"nctId":"NCT00343291","orgStudyIdInfo":{"id":"13421"},"secondaryIdInfos":[{"id":"I4E-MC-S001","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"CP02-0554","type":"OTHER","domain":"ImClone"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC","officialTitle":"Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2011-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12"},"primaryCompletionDateStruct":{"date":"2010-05","type":"ACTUAL"},"completionDateStruct":{"date":"2010-12","type":"ACTUAL"},"studyFirstSubmitDate":"2006-06-20","studyFirstSubmitQcDate":"2006-06-20","studyFirstPostDateStruct":{"date":"2006-06-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-05-13","resultsFirstSubmitQcDate":"2011-05-13","resultsFirstPostDateStruct":{"date":"2011-06-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-05-13","lastUpdatePostDateStruct":{"date":"2011-06-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Non-Small Cell Lung Cancer","Malignant pleural effusions"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":121,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","type":"ACTIVE_COMPARATOR","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200 mg/m² on day 1 of every 3 week cycle\n* Carboplatin area under curve (AUC=6 min\\*mg/mL) on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met","interventionNames":["Biological: Cetuximab","Biological: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","type":"ACTIVE_COMPARATOR","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met","interventionNames":["Biological: Cetuximab","Biological: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"BIOLOGICAL","name":"Cetuximab","description":"Administered intravenously","armGroupLabels":["Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)"],"otherNames":["Erbitux"]},{"type":"BIOLOGICAL","name":"Bevacizumab","description":"Administered intravenously","armGroupLabels":["Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)"]},{"type":"DRUG","name":"Paclitaxel","description":"Administered intravenously","armGroupLabels":["Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)"]},{"type":"DRUG","name":"Carboplatin","description":"Administered intravenously","armGroupLabels":["Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.","timeFrame":"Randomization to PD or date of death from any cause up to 33.1 months"}],"secondaryOutcomes":[{"measure":"Overall Survival","description":"Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.","timeFrame":"Randomization to the date of death from any cause up to 42.7 months"},{"measure":"Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)","description":"The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.","timeFrame":"Randomization to measured progressive disease up to 31.8 months"},{"measure":"Duration of Overall Response","description":"The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.","timeFrame":"Time of first response to the first date of PD or death due to any cause up to 31.8 months"},{"measure":"Percentage of Participants With Symptomatic Response (Symptom Response Rate)","description":"Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \\>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.","timeFrame":"From date of partial response until progression of disease up to 31.8 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has histologically or cytologically confirmed non-small cell lung cancer (NSCLC), except squamous cell carcinoma. Mixed tumors will be categorized by the predominant cell type, but the presence of small cell lung cancer elements will make the patient ineligible. Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy.\n* The patient has advanced NSCLC (Stage IIIB with malignant pleural effusion or Stage IV or recurrent disease).\n* Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).\n* The patient's Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1.\n* The patient has adequate hematologic function as defined by an Absolute Neutrophil Count greater than or equal to 1500/mm³,hemoglobin greater than or equal to 9 gm/dL, and a platelet count greater than or equal to 100,000/mm³ obtained within 2 weeks prior to the first dose of study medication.\n* The patient has adequate hepatic function as defined by a total bilirubin greater than or equal to 1.5 mg/dL and transaminases and alkaline phosphatase less than or equal to 5 x the Upper Limit of Normal (ULN) obtained within 2 weeks prior to the first dose of study medication.\n* The patient has adequate renal function as defined by serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance (CrCl) \\>60 mL/minute, and urine dipstick for proteinuria \\<1+ (ie, either 0 or trace) obtained within 2 weeks prior to the first dose of study medication. If urine dipstick is greater than or equal to 1+, then a 24-hour urine for protein must demonstrate \\<500 mg of protein in 24 hours to allow participation in the study.\n* The patient has adequate coagulation function as defined by International Normalized Ratio less than or equal to 1.5 and a Prothrombin time and partial thromboplastin time less than or equal to ULN obtained within 2 weeks prior to the first dose of study medication.\n* The patient, if a woman of childbearing potential, agrees to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study. If a male and sexually active, the patient agrees to use effective contraception.\n\nExclusion Criteria:\n\n* The patient has known Central Nervous System metastases. A head computed tomography (CT) is required within 4 weeks prior to the first dose of study medication (magnetic resonance imagines \\[MRIs\\] are also acceptable).\n* The patient has received prior cetuximab therapy.\n* The patient has received prior bevacizumab therapy.\n* The patient has received prior systemic chemotherapy or radiation therapy at any time for lung cancer.\n* Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with adequately treated cancers of other histologies who have been disease-free for more than 3 years prior to the first treatment dose are eligible.\n* Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy.\n* The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* The patient has a history of thrombotic or hemorrhagic disorders.\n* The patient has uncontrolled hypertension (\\>150/100 mmHg) on a standard regimen of anti-hypertensive therapy.\n* The patient is receiving chronic daily treatment with aspirin (\\>325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit platelet function.\n* The patient is receiving treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®) and /or cilostazol (Pletal®).\n* The patient is receiving anti-coagulation therapy. Prophylactic anti-coagulation of venous access devices is allowed. Caution should be taken on treating patients with low dose heparin or low molecular weight heparin for deep vein thrombosis (DVT) prophylaxis during treatment with bevacizumab as there may be an increased risk of bleeding.\n* Patients with a history of gross hemoptysis (defined as bright red blood or greater than or equal to ½ teaspoon).\n* The patient has a serious non-healing wound ulcer, bone fracture, or major surgical procedure within 30 days prior to first dose of study medication.\n* Elective or planned major surgery to be performed during the course of the trial.\n* The patient has a pre-existing neuropathy \\>grade 1.\n* The patient, if a woman, is pregnant or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Decatur","state":"Alabama","zip":"35601","country":"United States","geoPoint":{"lat":34.60593,"lon":-86.98334}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Huntsville","state":"Alabama","zip":"35805","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Scottsdale","state":"Arizona","zip":"85258","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Grass Valley","state":"California","zip":"95945","country":"United States","geoPoint":{"lat":39.21906,"lon":-121.06106}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Port Richey","state":"Florida","zip":"34655","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Augusta","state":"Georgia","zip":"30901","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gurnee","state":"Illinois","zip":"60031","country":"United States","geoPoint":{"lat":42.3703,"lon":-87.90202}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Louisville","state":"Kentucky","zip":"40215","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baltimore","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kalamazoo","state":"Michigan","zip":"49048","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lambertville","state":"Michigan","zip":"48144","country":"United States","geoPoint":{"lat":41.76588,"lon":-83.62799}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lansing","state":"Michigan","zip":"48910","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Las Vegas","state":"Nevada","zip":"89109","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"High Point","state":"North Carolina","zip":"27262","country":"United States","geoPoint":{"lat":35.95569,"lon":-80.00532}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Langhorne","state":"Pennsylvania","zip":"19047","country":"United States","geoPoint":{"lat":40.17455,"lon":-74.92267}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Philadelphia","state":"Pennsylvania","zip":"19114","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Willow Grove","state":"Pennsylvania","zip":"19090","country":"United States","geoPoint":{"lat":40.144,"lon":-75.11573}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29403","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hilton Head Island","state":"South Carolina","zip":"29926","country":"United States","geoPoint":{"lat":32.19382,"lon":-80.73816}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Johnson City","state":"Tennessee","zip":"37604","country":"United States","geoPoint":{"lat":36.31344,"lon":-82.35347}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Grapevine","state":"Texas","zip":"76051","country":"United States","geoPoint":{"lat":32.93429,"lon":-97.07807}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Houston","state":"Texas","zip":"77024","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"FG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"61"}]},{"type":"RECEIVED AT LEAST ONE DOSE OF STUDY DRUG","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Participants completed 6 cycles of treatment. Did not start subsequent weekly cetuximab monotherapy.","numSubjects":"3"},{"groupId":"FG001","comment":"Participants completed 6 cycles of treatment. Did not start subsequent weekly cetuximab monotherapy.","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"56"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"34"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"BG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"121"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.4","spread":"11.52"},{"groupId":"BG001","value":"62.1","spread":"8.97"},{"groupId":"BG002","value":"62.8","spread":"10.29"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"< 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"63"}]}]},{"title":"≥ 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"58"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"< 70 years","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"92"}]}]},{"title":"≥ 70 years","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"29"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"52"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"69"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"106"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"121"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Full Active","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"53"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"55"}]}]},{"title":"Missing/Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Current","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"28"}]}]},{"title":"Past","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"81"}]}]},{"title":"Exposed to Second-hand Smoke","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]},{"title":"Not Exposed to Second-hand Smoke","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}]}]},{"title":"Missing/Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.","populationDescription":"Included all enrolled, randomized participants. All participants were analyzed as part of the treatment group to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to PD or date of death from any cause up to 33.1 months","groups":[{"id":"OG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"OG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","lowerLimit":"5.65","upperLimit":"7.03"},{"groupId":"OG001","value":"4.50","lowerLimit":"4.01","upperLimit":"5.42"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.","populationDescription":"Included all enrolled, randomized participants. All participants were analyzed as part of the treatment group to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to the date of death from any cause up to 42.7 months","groups":[{"id":"OG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"OG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.06","lowerLimit":"9.40","upperLimit":"19.25"},{"groupId":"OG001","value":"11.63","lowerLimit":"6.64","upperLimit":"17.61"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)","description":"The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.","populationDescription":"Included all enrolled, randomized participants. All participants were analyzed as part of the treatment group to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to measured progressive disease up to 31.8 months","groups":[{"id":"OG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"OG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","lowerLimit":"39.0","upperLimit":"64.3"},{"groupId":"OG001","value":"44.3","lowerLimit":"31.8","upperLimit":"56.7"}]}]}]},{"type":"SECONDARY","title":"Duration of Overall Response","description":"The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.","populationDescription":"Included all enrolled, randomized participants with a best overall response of CR or PR (responders). All participants were analyzed as part of the treatment group to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time of first response to the first date of PD or death due to any cause up to 31.8 months","groups":[{"id":"OG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"OG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.86","lowerLimit":"4.30","upperLimit":"7.16"},{"groupId":"OG001","value":"3.94","lowerLimit":"2.92","upperLimit":"4.47"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Response (Symptom Response Rate)","description":"Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \\>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.","populationDescription":"Included all enrolled, randomized participants with a score of ≤26 at baseline. All participants were analyzed as part of the treatment group to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of partial response until progression of disease up to 31.8 months","groups":[{"id":"OG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"},{"id":"OG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","lowerLimit":"27.1","upperLimit":"56.6"},{"groupId":"OG001","value":"38.6","lowerLimit":"24.2","upperLimit":"53.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Adverse events include all grades, regardless of severity or possible causality.","eventGroups":[{"id":"EG000","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n* Paclitaxel 200mg/m² on day 1 of every 3 week cycle\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of every 3 week cycle\n\nPatients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met","seriousNumAffected":38,"seriousNumAtRisk":58,"otherNumAffected":56,"otherNumAtRisk":58},{"id":"EG001","title":"Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)","description":"Cycles 1-6:\n\n* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week\n* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle\n\nCycles 1-3:\n\n* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles\n* Carboplatin AUC=6 min\\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met","seriousNumAffected":28,"seriousNumAtRisk":58,"otherNumAffected":57,"otherNumAtRisk":58}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58}]},{"term":"Pseudomonal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Iga nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Renal tubular disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Epididymitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Hydropneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58}]},{"term":"Pulmonary thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Aortic embolus","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Iliac artery embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":21,"numAtRisk":58},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":58}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":17,"numAtRisk":58},{"groupId":"EG001","numEvents":21,"numAffected":14,"numAtRisk":58}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":11,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":58}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":58},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":58}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":22,"numAtRisk":58},{"groupId":"EG001","numEvents":20,"numAffected":16,"numAtRisk":58}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":22,"numAtRisk":58},{"groupId":"EG001","numEvents":27,"numAffected":14,"numAtRisk":58}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":58}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":30,"numAtRisk":58},{"groupId":"EG001","numEvents":32,"numAffected":23,"numAtRisk":58}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":19,"numAtRisk":58},{"groupId":"EG001","numEvents":29,"numAffected":23,"numAtRisk":58}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":58},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":58}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":58}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":32,"numAtRisk":58},{"groupId":"EG001","numEvents":41,"numAffected":28,"numAtRisk":58}]},{"term":"Infusion related reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":13,"numAffected":4,"numAtRisk":58}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":58}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":58}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":6,"numAtRisk":58},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":58}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":10,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":17,"numAtRisk":58},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":58}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":58}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":58}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":19,"numAtRisk":58},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":58}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":58},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":58}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":58}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":58}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":58}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":17,"numAtRisk":58},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":58}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":58}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":6,"numAtRisk":58},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":58}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":58}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":58},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":58}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":58},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":58}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":58},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":58}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":58}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":58},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":58}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":5,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":58}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":58},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":58}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58}]},{"term":"Postnasal drip","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":58},{"groupId":"EG001","numEvents":27,"numAffected":22,"numAtRisk":58}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":45,"numAtRisk":58},{"groupId":"EG001","numEvents":74,"numAffected":40,"numAtRisk":58}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":58},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":58}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":15,"numAffected":10,"numAtRisk":58}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":58}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":58}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":58}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":58}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D016066","term":"Pleural Effusion, Malignant"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D010997","term":"Pleural Neoplasms"},{"id":"D010996","term":"Pleural Effusion"},{"id":"D010995","term":"Pleural Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068818","term":"Cetuximab"},{"id":"D000068258","term":"Bevacizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}